Lumetry Diagnostics: Raiffeisenbank invests in Graz-based MedTech company
Raiffeisenlandesbank Niederösterreich-Wien is taking a 10 percent stake in Lumetry Diagnostics as lead investor; the investment amount was not disclosed. The capital will help the Graz-based MedTech company launch the first CE-marked product version of its breath-analysis device for COPD patients in Europe. The device combines spirometry and capnography; AI-powered algorithms for a follow-up model are undergoing clinical trials.